Grifols: the board considers that Brookfield’s indicative price undervalues the company Teva: S&P upgrades the rating to BB/positive from BB/positiveElior: Results recovered in 2023-24, exceeding expectations. Debt reduction is making headway as planned.Tereos: Sharp decline in EBITDA in Q2 24/25. The financial position is stable thanks to the generation of FCF.>...
Grifols : le conseil d’administration estime que le prix indicatif proposé par Brookfield sous-évalue la sociétéTeva: S&P upgrades the rating to BB/positive from BB/positiveElior: les résultats se sont redressés 2023/24, dépassant les attentes. Le désendettement progresse comme prévu.Tereos : fort repli de l'EBITDA au T2 24/25. La situation financière est stable grâce à la génération de FCF.>...
>Targets for 2028...and therefore very long term - At its CMD, Casino presented its main targets out to 2028. Specifically, we note a CAGR for business volumes (GMV) of around € 15bn (compared to c.€ 13bn in 2023), representing an average annual growth rate (CAGR) of +3.7% over the 2024-2028 period. The volume of business is data on which Casino intends to improve its communication, especially since its model will be more focused on franchising (90% by 2028).Conv...
>Des objectifs 2028… du très long terme donc… - Lors de son CMD, le groupe Casino a présenté ses principaux objectifs à horizon 2028. En particulier nous retenons un volume d’affaires (GMV) d’environ 15 Md€ (contre c.13 Md€ en 2023), soit un TMVA de 3,7% sur la période 2024-2028. Le volume d’affaires est une donnée sur laquelle Casino entend davantage communiquer, en particulier car son modèle sera davantage tourné vers la franchise (90% à horizon 2028).En revanc...
With management very pragmatic about its financial leeway, the 2028 plan looks more like a restructuring/optimisation operation than a relaunch. We remain more cautious on EBITDA recovery and FCF breakeven with unlevered FCF to turn positive in 2027 and levered FCF only beyond 2028. With no additio
>EBITDAaL just 0.7% and 0.9% above our estimates and the consensus - Cellnex’s Q3 2024 results were in line with our estimates and with the consensus at the operating level: revenues at € 982m (€ 987m ODDO BHF and € 982m css), with a slightly weaker performance from DAS and Services compensated by a better performance in France (probably partially impacted by the timing of the disposal of remedies within the quarter). An in-line performance in both opex and lease lia...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.